Research programme: peptide-based cancer therapeutics - ENKAMAlternative Names: Dekafin2; EncaminC; Inherbin3; Inherbins
Latest Information Update: 16 Jul 2016
At a glance
- Originator ENKAM Pharmaceuticals A/S
- Class Peptides
- Mechanism of Action Epidermal growth factor receptor antagonists; Fibroblast growth factor receptor agonists; Protein tyrosine kinase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Denmark (Parenteral)
- 12 Nov 2007 Preclinical trials in Solid tumours in Denmark (Parenteral)